Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials

by Howard L. Kaufman, Robert H. I. Andtbacka, Frances A. Collichio, Michael Wolf, Zhongyun Zhao, Mark Shilkrut, Igor Puzanov, Merrick Ross
Published 2017-09-01

Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

by Robert H. I. Andtbacka, Frances Collichio, Kevin J. Harrington, Mark R. Middleton, Gerald Downey, Katarina Ӧhrling, Howard L. Kaufman
Published 2019-06-01

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context

by Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert
Published 2019-09-01

SCF-KIT signaling induces endothelin-3 synthesis and secretion: Thereby activates and regulates endothelin-B-receptor for generating temporally- and spatially-precise nitric oxide...

by Lei L Chen, Jing Zhu, Jonathan Schumacher, Chongjuan Wei, Latha Ramdas, Victor G Prieto, Arnie Jimenez, Marco A Velasco, Sheryl R Tripp, Robert H I Andtbacka, Launce Gouw, George M Rodgers, Liansheng Zhang, Benjamin K Chan, Pamela B Cassidy, Robert S Benjamin, Sancy A Leachman, Marsha L Frazier
Published 2017-01-01